More than 100 trillion symbiotic microorganisms constitutively colonize throughout the human body, including the oral cavity, the skin, and the gastrointestinal tract. The oral cavity harbors one of the most diverse and abundant microbial communities within the human body, second to the community that resides in the gastrointestinal tract, and is composed of >770 bacterial species. Advances in sequencing technologies help define the precise microbial landscape in our bodies. Environmental and functional differences render the composition of resident microbiota largely distinct between the mouth and the gut and lead to the development of unique microbial ecosystems in the 2 mucosal sites. However, it is apparent that there may be a microbial connection between these 2 mucosal sites in the context of disease pathogenesis. Accumulating evidence indicates that resident oral bacteria can translocate to the gastrointestinal tract through hematogenous and enteral routes. The dissemination of oral microbes to the gut may exacerbate various gastrointestinal diseases, including irritable bowel syndrome, inflammatory bowel disease, and colorectal cancer. However, the precise role that oral microbes play in the extraoral organs, including the gut, remains elusive. Here, we review the recent findings on the dissemination of oral bacteria to the gastrointestinal tract and their possible contribution to the pathogenesis of gastrointestinal diseases. Although little is known about the mechanisms of ectopic colonization of the gut by oral bacteria, we also discuss the potential factors that allow the oral bacteria to colonize the gut.
AbedJEmgardJEZamirGFarojaMAlmogyGGrenovASolANaorRPikarskyEAtlanKA, et al. 2016. Fap2 mediates Fusobacterium nucleatum colorectal adenocarcinoma enrichment by binding to tumor-expressed Gal-GalNAc. Cell Host Microbe. 20(2):215–225.
2.
ArimatsuKYamadaHMiyazawaHMinagawaTNakajimaMRyderMIGotohKMotookaDNakamuraSIidaT, et al. 2014. Oral pathobiont induces systemic inflammation and metabolic changes associated with alteration of gut microbiota. Sci Rep. 4:4828.
3.
AtarashiKSudaWLuoCKawaguchiTMotooINarushimaSKiguchiYYasumaKWatanabeETanoueT, et al. 2017. Ectopic colonization of oral bacteria in the intestine drives TH1 cell induction and inflammation. Science. 358(6361):359–365.
4.
BaekKJiSChoiY. 2018. Complex intratissue microbiota forms biofilms in periodontal lesions. J Dent Res. 97(2):192–200.
5.
BlumHE. 2017. The human microbiome. Adv Med Sci. 62(2):414–420.
6.
CanavanCWestJCardT. 2014. The epidemiology of irritable bowel syndrome. Clin Epidemiol. 6:71–80.
7.
CastanerOGodayAParkYMLeeSHMagkosFShiowSTESchroderH. 2018. The gut microbiome profile in obesity: a systematic review. Int J Endocrinol. 2018:4095789.
8.
ChongPPChinVKLooiCYWongWFMadhavanPYongVC. 2019. The microbiome and irritable bowel syndrome—a review on the pathophysiology, current research and future therapy. Front Microbiol. 10:1136. Erratum in: Front Microbiol. 2019Aug13;10:1870.
9.
CostalongaMHerzbergMC. 2014. The oral microbiome and the immunobiology of periodontal disease and caries. Immunol Lett. 162(2 Pt A):22–38.
10.
CrakesKRJiangG. 2019. Gut microbiome alterations during hiv/siv infection: implications for HIV cure. Front Microbiol. 10:1104.
11.
EscapaIFChenTHuangYGajarePDewhirstFELemonKP. 2018. New insights into human nostril microbiome from the expanded Human Oral Microbiome Database (eHOMD): a resource for the microbiome of the human aerodigestive tract. mSystems. 3(6):e00187-18.
12.
GengJSongQTangXLiangXFanHPengHGuoQZhangZ. 2014. Co-occurrence of driver and passenger bacteria in human colorectal cancer. Gut Pathog. 6:26.
13.
Geva-ZatorskyNSefikEKuaLPasmanLTanTGOrtiz-LopezAYanortsangTBYangLJuppRMathisD, et al. 2017. Mining the human gut microbiota for immunomodulatory organisms. Cell. 168(5):928–943, e911.
14.
GeversDKugathasanSDensonLAVazquez-BaezaYVan TreurenWRenBSchwagerEKnightsDSongSJYassourM, et al. 2014. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 15(3):382–392.
15.
GilbertJABlaserMJCaporasoJGJanssonJKLynchSVKnightR. 2018. Current understanding of the human microbiome. Nat Med. 24(4):392–400.
16.
GravesDTCorreaJDSilvaTA. 2019. The oral microbiota is modified by systemic diseases. J Dent Res. 98(2):148–156.
17.
GuoSLiLXuBLiMZengQXiaoHXueYWuYWangYLiuW, et al. 2018. A simple and novel fecal biomarker for colorectal cancer: ratio of Fusobacterium nucleatum to probiotics populations, based on their antagonistic effect. Clin Chem. 64(9):1327–1337.
18.
GurCIbrahimYIsaacsonBYaminRAbedJGamlielMEnkJBar-OnYStanietsky-KaynanNCoppenhagen-GlazerS, et al. 2015. Binding of the Fap2 protein of Fusobacterium nucleatum to human inhibitory receptor tigit protects tumors from immune cell attack. Immunity. 42(2):344–355.
19.
HaNHWooBHKimDJHaESChoiJIKimSJParkBSLeeJHParkHR. 2015. Prolonged and repetitive exposure to Porphyromonas gingivalis increases aggressiveness of oral cancer cells by promoting acquisition of cancer stem cell properties. Tumour Biol. 36(12):9947–9960.
20.
HajishengallisG. 2015. Periodontitis: from microbial immune subversion to systemic inflammation. Nat Rev Immunol. 15(1):30–44.
HorlianaACChambroneLFozAMArteseHPRabelo MdeSPannutiCMRomitoGA. 2014. Dissemination of periodontal pathogens in the bloodstream after periodontal procedures: a systematic review. PLoS One. 9(5):e98271.
23.
HugerthLWAndreassonATalleyNJForsbergAMKjellströmLSchmidtPTAgreusLEngstrandL. 2020. No distinct microbiome signature of irritable bowel syndrome found in a Swedish random population. Gut. 69:1076–1084.
24.
Human Microbiome Project Consortium. 2012. A framework for human microbiome research. Nature. 486(7402):215–221.
25.
HumphreySPWilliamsonRT. 2001. A review of saliva: normal composition, flow, and function. J Prosthet Dent. 85(2):162–169.
26.
InabaHAmanoALamontRJMurakamiY. 2015. Involvement of protease-activated receptor 4 in over-expression of matrix metalloproteinase 9 induced by Porphyromonas gingivalis. Med Microbiol Immunol. 204(5):605–612.
27.
InabaHSugitaHKuboniwaMIwaiSHamadaMNodaTMorisakiILamontRJAmanoA. 2014. Porphyromonas gingivalis promotes invasion of oral squamous cell carcinoma through induction of proMMP9 and its activation. Cell Microbiol. 16(1):131–145.
28.
KamadaNChenGYInoharaNNunezG. 2013. Control of pathogens and pathobionts by the gut microbiota. Nat Immunol. 14(7):685–690.
29.
KamadaNSeoSUChenGYNunezG. 2013. Role of the gut microbiota in immunity and inflammatory disease. Nat Rev Immunol. 13(5):321–335.
30.
KassinenAKrogius-KurikkaLMakivuokkoHRinttilaTPaulinLCoranderJMalinenEApajalahtiJPalvaA. 2007. The fecal microbiota of irritable bowel syndrome patients differs significantly from that of healthy subjects. Gastroenterology. 133(1):24–23.
31.
KilianM. 2018. The oral microbiome—friend or foe?Eur J Oral Sci. 126Suppl 1:5–12.
32.
KomiyaYShimomuraYHigurashiTSugiYArimotoJUmezawaSUchiyamaSMatsumotoMNakajimaA. 2019. Patients with colorectal cancer have identical strains of Fusobacterium nucleatum in their colorectal cancer and oral cavity. Gut. 68(7):1335–1337.
33.
KosticADChunERobertsonLGlickmanJNGalliniCAMichaudMClancyTEChungDCLochheadPHoldGL, et al. 2013. Fusobacterium nucleatum potentiates intestinal tumorigenesis and modulates the tumor-immune microenvironment. Cell Host Microbe. 14(2):207–215.
34.
KuboniwaMHasegawaYMaoSShizukuishiSAmanoALamontRJYilmazO. 2008. P. gingivalis accelerates gingival epithelial cell progression through the cell cycle. Microbes Infect. 10(2):122–128.
35.
Lloyd-PriceJArzeCAnanthakrishnanANSchirmerMAvila-PachecoJPoonTWAndrewsEAjamiNJBonhamKSBrislawnCJ, et al. 2019. Multi-omics of the gut microbial ecosystem in inflammatory bowel diseases. Nature. 569(7758):655–662.
36.
LockhartPBBrennanMTSasserHCFoxPCPasterBJBahrani-MougeotFK. 2008. Bacteremia associated with toothbrushing and dental extraction. Circulation. 117(24):3118–3125.
37.
LovellRMFordAC. 2012. Global prevalence of and risk factors for irritable bowel syndrome: a meta-analysis. Clin Gastroenterol Hepatol. 10(7):712–721, e714.
38.
MaoSParkYHasegawaYTribbleGDJamesCEHandfieldMStavropoulosMFYilmazOLamontRJ. 2007. Intrinsic apoptotic pathways of gingival epithelial cells modulated by Porphyromonas gingivalis. Cell Microbiol. 9(8):1997–2007.
39.
Momen-HeraviFBabicATworogerSSZhangLWuKSmith-WarnerSAOginoSChanATMeyerhardtJGiovannucciE, et al. 2017. Periodontal disease, tooth loss and colorectal cancer risk: results from the Nurses’ Health Study. Int J Cancer. 140(3):646–652.
40.
MoranCJWaltersTDGuoCHKugathasanSKleinCTurnerDWoltersVMBandsmaRHMouzakiMZachosM, et al. 2013. IL-10R polymorphisms are associated with very-early-onset ulcerative colitis. Inflamm Bowel Dis. 19(1):115–123.
41.
NakajimaMArimatsuKKatoTMatsudaYMinagawaTTakahashiNOhnoHYamazakiK. 2015. Oral administration of P. gingivalis induces dysbiosis of gut microbiota and impaired barrier function leading to dissemination of enterobacteria to the liver. PLoS One. 10(7):e0134234.
42.
OhmanLSimrenM. 2010. Pathogenesis of ibs: role of inflammation, immunity and neuroimmune interactions. Nat Rev Gastroenterol Hepatol. 7(3):163–173.
43.
OhmanLTornblomHSimrenM. 2015. Crosstalk at the mucosal border: importance of the gut microenvironment in IBS. Nat Rev Gastroenterol Hepatol. 12(1):36–49.
44.
PaganelliFLLuyerMHazelbagCMUhHWRogersMRCAdriaansDBerbersRMHendrickxAPAViveenMCGrootJA, et al. 2019. Roux-Y gastric bypass and sleeve gastrectomy directly change gut microbiota composition independent of surgery type. Sci Rep. 9(1):10979.
45.
PanCXuXTanLLinLPanY. 2014. The effects of Porphyromonas gingivalis on the cell cycle progression of human gingival epithelial cells. Oral Dis. 20(1):100–108.
PedersenAMBardowAJensenSBNauntofteB. 2002. Saliva and gastrointestinal functions of taste, mastication, swallowing and digestion. Oral Dis. 8(3):117–129.
48.
PhamVTLacroixCBraeggerCPChassardC. 2017. Lactate-utilizing community is associated with gut microbiota dysbiosis in colicky infants. Sci Rep. 7(1):11176.
49.
PittayanonRLauJTYuanYLeontiadisGITseFSuretteMMoayyediP. 2019. Gut microbiota in patients with irritable bowel syndrome—a systematic review. Gastroenterology. 157(1):97–108.
50.
QinJLiRRaesJArumugamMBurgdorfKSManichanhCNielsenTPonsNLevenezFYamadaT, et al. 2010. A human gut microbial gene catalogue established by metagenomic sequencing. Nature. 464(7285):59–65.
51.
Rajilic-StojanovicMBiagiEHeiligHGKajanderKKekkonenRATimsSde VosWM. 2011. Global and deep molecular analysis of microbiota signatures in fecal samples from patients with irritable bowel syndrome. Gastroenterology. 141(5):1792–1801.
52.
RubinsteinMRWangXLiuWHaoYCaiGHanYW. 2013. Fusobacterium nucleatum promotes colorectal carcinogenesis by modulating e-cadherin/beta-catenin signaling via its fadA adhesin. Cell Host Microbe. 14(2):195–206.
53.
SartorRB. 2008. Microbial influences in inflammatory bowel diseases. Gastroenterology. 134(2):577–594.
54.
SchmidtTSHaywardMRCoelhoLPLiSSCosteaPIVoigtAYWirbelJMaistrenkoOMAlvesRJBergstenE, et al. 2019. Extensive transmission of microbes along the gastrointestinal tract. Elife. 8:e42693.
55.
SekirovIRussellSLAntunesLCFinlayBB. 2010. Gut microbiota in health and disease. Physiol Rev. 90(3):859–904.
56.
SenderRFuchsSMiloR. 2016. Revised estimates for the number of human and bacteria cells in the body. PLoS Biol. 14(8):e1002533.
57.
SimrenMTackJ. 2018. New treatments and therapeutic targets for IBS and other functional bowel disorders. Nat Rev Gastroenterol Hepatol. 15(10):589–605.
58.
SocranskySSHaffajeeADCuginiMASmithCKentRLJr.1998. Microbial complexes in subgingival plaque. J Clin Periodontol. 25(2):134–144.
59.
SoutoRAde AndradeAFBUzedaMColomboA. 2006. Prevalence of “non-oral” pathogenic bacteria in subgingival biofilm of subjects with chronic periodontitis. Braz J Microbiol. 37(3):208–215.
60.
TagainoRWashioJAbikoYTandaNSasakiKTakahashiN. 2019. Metabolic property of acetaldehyde production from ethanol and glucose by oral streptococcus and neisseria. Sci Rep. 9(1):10446.
61.
ThomasAMManghiPAsnicarFPasolliEArmaniniFZolfoMBeghiniFManaraSKarcherNPozziC, et al. 2019. Metagenomic analysis of colorectal cancer datasets identifies cross-cohort microbial diagnostic signatures and a link with choline degradation. Nat Med. 25(4):667–678.
62.
TsukasakiMKomatsuNNagashimaKNittaTPluemsakunthaiWShukunamiCIwakuraYNakashimaTOkamotoKTakayanagiH. 2018. Host defense against oral microbiota by bone-damaging T cells. Nat Commun. 9(1):701.
63.
Vich VilaAImhannFCollijVJankipersadsingSAGurryTMujagicZKurilshikovABonderMJJiangXTigchelaarEF, et al. 2018. Gut microbiota composition and functional changes in inflammatory bowel disease and irritable bowel syndrome. Sci Transl Med. 10(472):eaap8914.
64.
WalkerMYPratapSSoutherlandJHFarmer-DixonCMLakshmyyaKGangulaPR. 2018. Role of oral and gut microbiome in nitric oxide-mediated colon motility. Nitric Oxide. 73:81–88.
65.
WangHFLiLFGuoSHZengQYNingFLiuWLZhangG. 2016. Evaluation of antibody level against Fusobacterium nucleatum in the serological diagnosis of colorectal cancer. Sci Rep. 6:33440.
66.
WirbelJPylPTKartalEZychKKashaniAMilaneseAFleckJSVoigtAYPallejaAPonnuduraiR, et al. 2019. Meta-analysis of fecal metagenomes reveals global microbial signatures that are specific for colorectal cancer. Nat Med. 25(4):679–689.
67.
WyattGMBaylissCELakeyAFBradleyHKHunterJOJonesVA. 1988. The faecal flora of two patients with food-related irritable bowel syndrome during challenge with symptom-provoking foods. J Med Microbiol. 26(4):295–299.
68.
YachidaSMizutaniSShiromaHShibaSNakajimaTSakamotoTWatanabeHMasudaKNishimotoYKuboM, et al. 2019. Metagenomic and metabolomic analyses reveal distinct stage-specific phenotypes of the gut microbiota in colorectal cancer. Nat Med. 25(6):968–976.
69.
YaoLJermanusCBarbettaBChoiCVerbekePOjciusDMYilmazO. 2010. Porphyromonas gingivalis infection sequesters pro-apoptotic Bad through Akt in primary gingival epithelial cells. Mol Oral Microbiol. 25(2):89–101.
70.
YilmazOJungasTVerbekePOjciusDM. 2004. Activation of the phosphatidylinositol 3-kinase/akt pathway contributes to survival of primary epithelial cells infected with the periodontal pathogen Porphyromonas gingivalis. Infect Immun. 72(7):3743–3751.
71.
YilmazOYaoLMaedaKRoseTMLewisELDumanMLamontRJOjciusDM. 2008. ATP scavenging by the intracellular pathogen Porphyromonas gingivalis inhibits P2X7-mediated host-cell apoptosis. Cell Microbiol. 10(4):863–875.
72.
YuTGuoFYuYSunTMaDHanJQianYKryczekISunDNagarshethN, et al. 2017. Fusobacterium nucleatum promotes chemoresistance to colorectal cancer by modulating autophagy. Cell. 170(3):548–563.e16.
73.
ZawadzkiPJPerkowskiKStarosciakBBaltazaWPadzikMPionkowskiKChomiczL. 2016. Identification of infectious microbiota from oral cavity environment of various population group patients as a preventive approach to human health risk factors. Ann Agric Environ Med. 23(4):566–569.
74.
ZhouYSztukowskaMWangQInabaHPotempaJScottDAWangHLamontRJ. 2015. Noncanonical activation of beta-catenin by Porphyromonas gingivalis. Infect Immun. 83(8):3195–3203.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
